NeOnc Technologies Holdings, Inc. filed an 8-K on November 18, 2026, disclosing an open-market share purchase by its CEO and updated interim clinical results from its NEO100-01 Phase 2a study.

Key Highlights

  • CEO share purchase: Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer, purchased an aggregate of 30,000 shares of common stock on the open market on November 13, 2026.
  • Updated objective response rate: The NEO100 Phase 2a study now shows an objective response rate of 12.5%, up from 8.3%, as assessed using RANO 2.0 criteria.
  • Total responses confirmed: The company disclosed 3 responses out of 24 patients in the NEO100 Phase 2a study.
  • Revised investor presentation: The company furnished an updated presentation superseding an earlier version previously furnished on November 16, 2026, covering current operations and clinical development.
  • Forward-looking statements: The presentation contains forward-looking statements, with associated risks and uncertainties discussed on Page 3 of the presentation, according to the filing.

NeOnc Discloses CEO Stock Purchase and NEO100 Clinical Update

According to the filing, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) reported two separate disclosures under Item 7.01 Regulation FD. The first, announced in a press release dated November 16, 2026, confirmed that Amir F. Heshmatpour, the company's Executive Chairman, President and Chief Executive Officer, purchased an aggregate of 30,000 shares of the company's common stock on the open market on November 13, 2026.

The second disclosure, announced in a press release dated November 17, 2026, provided updated interim results from the Phase 2a portion of the company's NEO100-01 clinical study of intranasal NEO100. The filing states that the company "confirmed an additional response in the NEO100 Phase 2a study, bringing the total number of responses to 3 of 24 patients and increasing the objective response rate from 8.3% to 12.5%, as assessed using RANO 2.0 criteria." This update appears on slides 16 and 17 of the revised investor presentation furnished as Exhibit 99.3.

The company noted that the revised presentation supersedes in its entirety the version previously furnished on November 16, 2026. The filing specifies that the information furnished under Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference. The company also stated it "makes no admission as to the materiality of any information included under this Item 7.01."

What Was Disclosed

NeOnc Technologies Holdings filed an 8-K disclosing a 30,000-share open-market purchase by its CEO on November 13, 2026, and updated Phase 2a clinical results for NEO100 showing an objective response rate of 12.5% across 3 of 24 patients, up from 8.3%.